Mainstay hopes US regulator will approve back pain device in 2020

Mainstay hopes US regulator will approve back pain device in 2020

Company says it will need to raise €45 million if it gets FDA green light

Mainstay Medical has said it will need to raise about $50 million (€45 million) if it secures approval from drug regulators to launch its chronic back pain treatment in America

Dublin stock market-listed Mainstay has submitted its treatment for pre-market approval by the US Food & Drug Administration (FDA) and is hopeful of securing the green light late next year.

Jason Hannon, Mainstay’s chief executive, said data submitted to the FDA based on patients using its treatment...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post